Cargando…
Connecting genetics and gene expression data for target prioritisation and drug repositioning
Developing new drugs continues to be a highly inefficient and costly business. By repurposing an existing compound for a different indication, drug repositioning offers an attractive alternative to traditional drug discovery. Most of these approaches work by matching transcriptional disease signatur...
Autores principales: | Ferrero, Enrico, Agarwal, Pankaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984374/ https://www.ncbi.nlm.nih.gov/pubmed/29881461 http://dx.doi.org/10.1186/s13040-018-0171-y |
Ejemplares similares
-
Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies
por: Ferrero, Enrico
Publicado: (2018) -
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
por: Zhu, Sha, et al.
Publicado: (2022) -
Systematic Drug Repositioning Based on Clinical Side-Effects
por: Yang, Lun, et al.
Publicado: (2011) -
From drug repositioning to target repositioning: prediction of therapeutic targets using genetically perturbed transcriptomic signatures
por: Namba, Satoko, et al.
Publicado: (2022) -
Drug repositioning for idiopathic epilepsy using gene expression signature data
por: Kumar, Pawan, et al.
Publicado: (2022)